JDRF T1D Fund
Impact investorBoston · Seed–Late Stage · 30 people tracked
Investment thesis
The T1D Fund deploys catalytic capital and scientific expertise to accelerate treatments and cures for type 1 diabetes. It positions itself as a collaboration platform that de-risks investments to draw additional investors into the T1D space, creating a flywheel effect. The fund partners with innovators advancing disease-modifying therapies and reinvests all returns to sustain a continuous cycle that funds foundational research and program development. Its team combines venture, investment banking, pharmaceutical, company-building, and business development experience, and it manages an active portfolio of more than 25 companies focused on curing and treating T1D.
Source: firm website, verified Aug 3, 2026.
Team · 30 people
from the firm's website & curated & public directories
What they invest in
from 28 of 33 portfolio companiesBiotech ×27Healthtech ×17Medical Devices ×14Digital Health ×6AI & Machine Learning ×4Deep Tech ×4Longevity ×1
HQs:United States×11France×2Canada×1Italy×1
Who they back
founder profiles across 11 portfolio companiesFounding team size:solo founder×42 founders×23 founders×34+ founders×2
Investments · 33 tracked
founders shown can be your intro pathBy year:2023 · 12022 · 12021 · 24 dated
Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
BiotechHealthtechAbingdon, Oxfordshire
Brian Di Donato(Chief Financial Officer)David Berman(Head of Research and Development)inTina St. Leger(Chief Human Resources Officer)inBahija Jallal(Chief Executive Officer)inRobert Perez(Director)Peter Ratcliffe(Director)
Co-investorsAvego BioScience Capital
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.
BiotechDigital HealthMedical DevicesHigh Point, US
Rudy Howard(Executive Officer)inStephen Holcombe(Executive Officer)inLarry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)Paul Meister(Director)Paul Savas(Director)
Co-investorsSamsara BioCapital
ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses.
BiotechDeep Tech
Co-investorsVivo Capital
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)
Co-investorsARCH Venture PartnersLux CapitalF-Prime CapitalGV (Google Ventures)Newpath Partners
Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues.
AI & Machine LearningBiotechLongevity
Tamer Mohamed(Founder & CEO)inSam Wadsworth(Co-founder & Chief Scientific Officer)inSimon Beyer(Co-founder & Chief Technology Officer)inLeela Paris(Chief Technical Operations Officer)inMike Scott(Chief Development Officer)inRay Smith(Chief Financial Officer)in
Co-investorsAngel ForumCivilization Ventures Management, LlcInBC Investment Corp.Page One VenturesPallasite VenturesPangaea Ventures Us Inc.+4 more
Digital HealthHealthtechMedical DevicesNew York, US
Jeffrey Brewer(Executive Officer, Director)Bryan Mazlish(Executive Officer, Director)Jon Brilliant(Executive Officer)
Co-investorsXplorer CapitalJanus Henderson InvestorsSmile GroupVisionnaire Ventures, Llc
Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)
BoardDaniel Bradbury(Director)inLana Ghanem(Director)
Co-investorsAlpha Wave GlobalBeyond CapitalBioBritAphelion CapitalHikma VenturesLifeSci Venture Partners+1 more
Co-investorsAEON Foundry
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.
BiotechHealthtech
Co-investorsAlpha Wave GlobalLumira VenturesRoche Venture FundAngelini Ventures
BiotechHealthtechCleveland, US
Robert Geho(Executive Officer, Director)W. Blair Geho(Executive Officer, Director)Helga Kautsky(Executive Officer)
BoardMichele Ollier(Director)Guiseppe Zocco(Director)Richard Caruso(Director)
Co-investorsMedicxi
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in
Co-investorsAdBio partnersRoche Venture FundBoehringer Ingelheim Venture FundSunstone Capital
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.
Biotech
Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in
BoardMichel Detheux(Chairman)in
Co-investorsEQT Life SciencesFund+
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.
AI & Machine LearningBiotechMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Co-investorsNewpath Partners
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsSofinnova PartnersIndaco Venture PartnersRoche Venture FundAbbVie
GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.
BiotechHealthtechMedical Devices
Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)David Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)inTom Wickham(Chief Scientific Officer)
Co-investorsNovartis Venture FundOrbiMedRA Capital
Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology
BiotechSaratoga, US
Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in
Co-investors7G BioVenturesSanofi Ventures
Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers.
Biotech
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsAmorChemGenesys CapitalNew Enterprise Associates (NEA)Tarnagulla Ventures
Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.
BiotechHealthtechMedical Devices
Joseph Nolanin
Co-investorsAIFARCH Venture PartnersSamsung Ventures
Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.
BiotechHealthtechMorrisville, US
Shankar Ramaswamy(Co-Founder, Chairman & CEO)inRoger Jeffs(Co-Founder & Vice Chairman)inFraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)inShankar Ramaswamy, M.D.(Founder)inMichele Stone(Chief Scientific Officer)inKatherine Eade(Chief Legal Officer)
Co-investorsPatient Square CapitalPremji InvestAmplo VenturesBluebird VenturesForesite CapitalNarya Capital+2 more
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova PartnersAlexandria+3 more
Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Torben Straight Nissen(Chief Executive Officer)Anthony Coyle(President, Research and Development)Robert Andtbacka(Chief Medical Officer)John Delyani(Chief Business Officer)Jan Kisielow(Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.)
Co-investorsFlagship PioneeringSoftBank Vision Fund
SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates.
BiotechDigital HealthHealthtechMedical Devices
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Steve Harr(President and Chief Executive Officer)
Co-investorsAmerican Family VenturesARCH Venture PartnersF-Prime CapitalFlagship PioneeringInnovating CapitalManta Ray Ventures+1 more
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
Co-investorsARCH Venture PartnersSlater Technology FundEight Roads VenturesMPM BioImpact
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.
BiotechHealthtechGermantown, US
William L. Rust(Executive Officer, Director, Promoter)Carole Welsch(Executive Officer)Gi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)
BoardJames N. Topper(Director)
Co-investorsMaryland TEDCOTEDCOFrazier Life Sciences
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)in
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesLAVLifeforce CapitalLilly Asia Ventures+1 more
Co-investorsToronto Innovation Acceleration Partners
Exits · 4
IPOs and acquisitions across the tracked portfolioImmunocoreNASDAQ: IMCRVtvtherapeuticsNASDAQ: VTVTInversagoacq. by Novo NordiskProventionbioacq. by Sanofi
Portfolio news
latest coverage across their companies
Kriya Therapeutics · nasdaqprivatemarket.com · Apr 3, 2026
Aera Therapeutics · ainvest.com · Mar 22, 2026
Jaguar Gene Therapy · clinicaltrialsarena.com · Feb 25, 2026
Biolinq · fiercebiotech.com · Sep 29, 2025
Seraxis · news.biobuzz.io · Jul 16, 2025
GentiBio · nasdaqprivatemarket.com · Jun 27, 2025
Frequently asked questions
- How many investments has JDRF T1D Fund made?
- JDRF T1D Fund has 28 tracked investments, 3 of which have exited via acquisition or IPO.
- What stage does JDRF T1D Fund invest at?
- JDRF T1D Fund invests at the Seed, Series A, Series B, Late Stage stages.
- What sectors does JDRF T1D Fund focus on?
- JDRF T1D Fund focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
- Where is JDRF T1D Fund located?
- JDRF T1D Fund is headquartered in Boston, US.
- Who does JDRF T1D Fund co-invest with?
- JDRF T1D Fund most often shares deals with ARCH Venture Partners, Alpha Wave Global, F-Prime Capital, among 56 tracked co-investors.
Images
Co-investors · 7
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Boehringer Ingelheim Venture Fund, established in 2010, invests in biotechnology companies developing therapeutics in immuno-oncology, regenerative medicine, and gene therapy, including platform technologies and novel vaccines. The fund targets early-stage companies addressing unmet medical needs through translational research and scientific innovation.
Domain Associates is a venture capital firm founded in 1985 that invests in life sciences companies. The firm operates as a limited liability company.
Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.
Cultivian Sandbox Ventures is a venture capital firm investing in innovative food and agriculture companies that commercialize solutions across the food and agriculture value chain.
Firms observed investing alongside JDRF T1D Fund, from public investor directories. Shared companies are the overlap with JDRF T1D Fund's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Gilde Healthcare is a specialist investment firm managing healthcare and climate-focused funds across venture & growth, and private equity strategies with a transatlantic team of sector specialists.
Syridex Bio identifies emerging areas of science and medicine to invest in innovations addressing unmet medical needs, applying a health-equity lens to opportunities that can improve outcomes across diverse patient populations.
iNetworks is a private equity investment fund and advisory practice founded in 1999, focused on funding disruptive healthcare, life science, and technology companies while providing operational expertise and long-term partnership.